{
    "organizations": [],
    "uuid": "972be27a04a84124723520127c9bbcf4ba1987fc",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-fda-accepts-new-drug-applications/brief-fda-accepts-new-drug-applications-for-mercks-doravirine-idUSASB0C00E",
    "ord_in_thread": 0,
    "title": "BRIEF-FDA Accepts New Drug Applications For Merck's Doravirine",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Jan 8 (Reuters) - Merck & Co Inc:\n* FDA ACCEPTS NEW DRUG APPLICATIONS FOR MERCK’S DORAVIRINE, THE COMPANY’S INVESTIGATIONAL NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI), FOR TREATMENT OF HIV-1 INFECTION\n* MERCK & CO INC - FDA HAS SET A TARGET ACTION DATE OF OCT. 23, 2018, FOR BOTH APPLICATIONS UNDER PRESCRIPTION DRUG USER FEE ACT\n* FDA ACCEPTS NEW DRUG APPLICATIONS FOR MERCK’S DORAVIRINE, THE COMPANY’S INVESTIGATIONAL NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI), FOR TREATMENT OF HIV-1 INFECTION Source text for Eikon: Further company coverage:\n ",
    "published": "2018-01-08T19:32:00.000+02:00",
    "crawled": "2018-01-09T17:08:54.012+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "jan",
        "reuters",
        "merck",
        "co",
        "inc",
        "fda",
        "accepts",
        "new",
        "drug",
        "application",
        "merck",
        "doravirine",
        "company",
        "investigational",
        "reverse",
        "transcriptase",
        "inhibitor",
        "nnrti",
        "treatment",
        "infection",
        "merck",
        "co",
        "inc",
        "fda",
        "set",
        "target",
        "action",
        "date",
        "application",
        "prescription",
        "drug",
        "user",
        "fee",
        "act",
        "fda",
        "accepts",
        "new",
        "drug",
        "application",
        "merck",
        "doravirine",
        "company",
        "investigational",
        "reverse",
        "transcriptase",
        "inhibitor",
        "nnrti",
        "treatment",
        "infection",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}